About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage gene therapy company focused on delivering novel treatments for ocular and rare diseases. Specializing in leveraging its proprietary adeno-associated virus (AAV) technology to deliver targeted therapies directly to affected areas, the company is dedicated to addressing unmet medical needs. Current projects include advancing a robust pipeline of gene therapy candidates, with a lead focus on treating wet age-related macular degeneration (AMD), a serious eye condition that can lead to blindness. Adverum's objective is to pioneer transformative, one-time treatments that can sustainably improve the lives of patients suffering from ocular and rare diseases without the need for repeated interventions.
Snapshot
Operations
Products and/or services of Adverum Biotechnologies
- ADVM-022, a gene therapy candidate for wet age-related macular degeneration.
- Research in gene therapy aiming to treat rare diseases.
- Development of vector platforms for ocular gene therapy.
- Innovations in AAV vector technology for improved gene delivery.
- Partnerships to explore gene therapy applications beyond ophthalmology.
- Initiatives focused on manufacturing and scalability of gene therapies.
Adverum Biotechnologies executive team
- Dr. Laurent Fischer M.D.President, CEO & Director
- Ms. Linda M. Rubinstein M.A.CFO, Principal Financial Officer & Principal Accounting Officer
- Mr. Kishor Peter Soparkar J.D.Chief Operating Officer
- Dr. Setareh Seyedkazemi Pharm.D.Chief Development Officer
- Dr. Rabia Gurses Ozden M.D.Chief Medical Officer
- Dr. R. Andrew Ramelmeier Ph.D.Chief Technology Officer
- Dr. Romuald Corbau Ph.D.Chief Scientific Officer
- Ms. Aneta FergusonGeneral Counsel
- Ms. Dena HouseChief People Officer
- Ms. Carla FiankanSenior Vice President of Regulatory Affairs